{'fraction_non_alphanumeric': 0.01881331403762663, 'fraction_numerical': 0.002894356005788712, 'mean_word_length': 5.528301886792453, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Continuous glucose monitoring of patients with type 1- and type 2 diabetes on haemodialysis].

Artificial intelligence (AI) has the potential to increase quality and efficiency of breast cancer screening. Recent studies have provided comparative data on AI versus human performance in cancer detection with encouraging results, and commercially available AI systems are used worldwide as a clinical tool for mammography screening. There are, however, a number of methodological concerns in relation to the evaluation of AI systems. This review discusses these aspects as well as the opportunities and challenges of clinical validation and implementation in breast cancer screening practice.